183 related articles for article (PubMed ID: 38136994)
1. Molecular Characterization and Establishment of a Prognostic Model Based on Primary Immunodeficiency Features in Association with RNA Modifications in Triple-Negative Breast Cancer.
Xia H; Xu X; Guo Y; Deng X; Wang Y; Fu S
Genes (Basel); 2023 Dec; 14(12):. PubMed ID: 38136994
[TBL] [Abstract][Full Text] [Related]
2. Novel molecular insights into pyroptosis in triple-negative breast cancer prognosis and immunotherapy.
Yu B; Luo J; Yang Y; Zhen K; Shen B
J Gene Med; 2024 Jan; 26(1):e3645. PubMed ID: 38041540
[TBL] [Abstract][Full Text] [Related]
3. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
Cao T; Huang M; Huang X; Tang T
PeerJ; 2024; 12():e16935. PubMed ID: 38435998
[TBL] [Abstract][Full Text] [Related]
4. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
5. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
[TBL] [Abstract][Full Text] [Related]
6. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
Zhang J; Zhang M; Tian Q; Yang J
Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
[TBL] [Abstract][Full Text] [Related]
7. Development of an ubiquitin-proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple-negative breast cancer.
Chen X; Ren C; Zhou Z; Chen J; Fan X; Li X; Chen J; Zhu J
J Gene Med; 2024 Jan; 26(1):e3584. PubMed ID: 37605934
[TBL] [Abstract][Full Text] [Related]
8. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
10. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
Zhou Y; Che Y; Fu Z; Zhang H; Wu H
Front Public Health; 2022; 10():902378. PubMed ID: 35875026
[TBL] [Abstract][Full Text] [Related]
11. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs.
Pan W; Song K; Zhang Y; Yang C; Zhang Y; Ji F; Zhang J; Shi J; Wang K
Front Immunol; 2022; 13():982486. PubMed ID: 36119101
[TBL] [Abstract][Full Text] [Related]
12. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study.
Wang K; Li HL; Xiong YF; Shi Y; Li ZY; Li J; Zhang X; Li HY
Cancer Med; 2019 Feb; 8(2):686-700. PubMed ID: 30677255
[TBL] [Abstract][Full Text] [Related]
14. Construction of a prognostic model for triple-negative breast cancer based on immune-related genes, and associations between the tumor immune microenvironment and immunological therapy.
Zhu Y; Tao LF; Liu JY; Wang YX; Huang H; Jiang YN; Qian WF
Cancer Med; 2023 Jul; 12(14):15704-15719. PubMed ID: 37306188
[TBL] [Abstract][Full Text] [Related]
15. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Shen X; Zhong J; He J; Han J; Chen N
Front Immunol; 2022; 13():978092. PubMed ID: 36105819
[TBL] [Abstract][Full Text] [Related]
16. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
17. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
18. HSPA8 Is a New Biomarker of Triple Negative Breast Cancer Related to Prognosis and Immune Infiltration.
Ying B; Xu W; Nie Y; Li Y
Dis Markers; 2022; 2022():8446857. PubMed ID: 36452344
[TBL] [Abstract][Full Text] [Related]
19. A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer.
Liu J; Ling Y; Su N; Li Y; Tian S; Hou B; Luo S; Zhao L; Shi M
Transl Cancer Res; 2022 Jan; 11(1):181-192. PubMed ID: 35261895
[TBL] [Abstract][Full Text] [Related]
20. A CTL/M2 macrophage-related four-gene signature predicting metastasis-free survival in triple-negative breast cancer treated with adjuvant radiotherapy.
Ye Y; Ma J; Zhang Q; Xiong K; Zhang Z; Chen C; Xiao H; Wang D
Breast Cancer Res Treat; 2021 Nov; 190(2):329-341. PubMed ID: 34482483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]